Is APLT or PMVP more profitable?

PMV Pharmaceuticals' return on equity of -68.98% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% PMV Pharmaceuticals N/A -68.98% -62.70%

Is APLT or EDSA more profitable?

Edesa Biotech's return on equity of -286.52% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% Edesa Biotech N/A -286.52% -75.36%

Do analysts rate SCLX or APLT?

Applied Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is PDSB or APLT more profitable?

Applied Therapeutics' return on equity of -340.84% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -346.02% -102.36% Applied Therapeutics N/A -340.84% -175.00%

Is APLT or ENTX more profitable?

Entera Bio's return on equity of -83.31% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% Entera Bio N/A -83.31% -70.83%

Applied Therapeutics (APLT) Competitors

$0.10 0.00 (0.00%)

As of 06/8/2026

Compare

APLT vs. PMVP, EDSA, SCLX, PDSB, and ENTX

Should you buy Applied Therapeutics stock or one of its competitors? MarketBeat compares Applied Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Applied Therapeutics include PMV Pharmaceuticals (PMVP), Edesa Biotech (EDSA), Scilex (SCLX), PDS Biotechnology (PDSB), and Entera Bio (ENTX). These companies are all part of the "pharmaceutical products" industry.

How does Applied Therapeutics compare to PMV Pharmaceuticals?

Applied Therapeutics (NASDAQ:APLT) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Applied Therapeutics presently has a consensus target price of $1.00, suggesting a potential upside of 870.87%. PMV Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 376.19%. Given Applied Therapeutics' higher possible upside, equities analysts clearly believe Applied Therapeutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PMV Pharmaceuticals has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

PMV Pharmaceuticals' return on equity of -68.98% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

In the previous week, PMV Pharmaceuticals had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for PMV Pharmaceuticals and 0 mentions for Applied Therapeutics. PMV Pharmaceuticals' average media sentiment score of 1.57 beat Applied Therapeutics' score of 0.00 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
PMV Pharmaceuticals	Very Positive

Applied Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

Summary

PMV Pharmaceuticals beats Applied Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Applied Therapeutics compare to Edesa Biotech?

Applied Therapeutics (NASDAQ:APLT) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

In the previous week, Edesa Biotech had 4 more articles in the media than Applied Therapeutics. MarketBeat recorded 4 mentions for Edesa Biotech and 0 mentions for Applied Therapeutics. Edesa Biotech's average media sentiment score of 1.25 beat Applied Therapeutics' score of 0.00 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Edesa Biotech	Positive

Applied Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Edesa Biotech has lower revenue, but higher earnings than Applied Therapeutics. Edesa Biotech is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Applied Therapeutics presently has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Edesa Biotech has a consensus target price of $5.00, suggesting a potential upside of 1.21%. Given Applied Therapeutics' higher probable upside, equities research analysts plainly believe Applied Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Edesa Biotech's return on equity of -286.52% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Edesa Biotech	N/A	-286.52%	-75.36%

Summary

Edesa Biotech beats Applied Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Applied Therapeutics compare to Scilex?

Scilex (NASDAQ:SCLX) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Scilex has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

Applied Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Applied Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
Applied Therapeutics	N/A	-340.84%	-175.00%

69.7% of Scilex shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 4.1% of Scilex shares are held by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Scilex had 4 more articles in the media than Applied Therapeutics. MarketBeat recorded 4 mentions for Scilex and 0 mentions for Applied Therapeutics. Scilex's average media sentiment score of 0.47 beat Applied Therapeutics' score of 0.00 indicating that Scilex is being referred to more favorably in the media.

Company	Overall Sentiment
Scilex	Neutral
Applied Therapeutics	Neutral

Applied Therapeutics has lower revenue, but higher earnings than Scilex. Applied Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	1.98	-$358.73M	-$40.47	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Summary

Applied Therapeutics beats Scilex on 8 of the 15 factors compared between the two stocks.

How does Applied Therapeutics compare to PDS Biotechnology?

PDS Biotechnology (NASDAQ:PDSB) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

PDS Biotechnology has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

PDS Biotechnology has higher earnings, but lower revenue than Applied Therapeutics. PDS Biotechnology is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

PDS Biotechnology currently has a consensus target price of $9.00, indicating a potential upside of 773.79%. Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than PDS Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Applied Therapeutics' return on equity of -340.84% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
Applied Therapeutics	N/A	-340.84%	-175.00%

In the previous week, PDS Biotechnology had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for PDS Biotechnology and 0 mentions for Applied Therapeutics. PDS Biotechnology's average media sentiment score of 1.87 beat Applied Therapeutics' score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
PDS Biotechnology	Very Positive
Applied Therapeutics	Neutral

Summary

PDS Biotechnology and Applied Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Applied Therapeutics compare to Entera Bio?

Applied Therapeutics (NASDAQ:APLT) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 10.6% of Entera Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Applied Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 870.87%. Entera Bio has a consensus target price of $9.00, indicating a potential upside of 637.70%. Given Applied Therapeutics' higher possible upside, equities analysts clearly believe Applied Therapeutics is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Entera Bio has lower revenue, but higher earnings than Applied Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Entera Bio	$40K	1,503.35	-$11.44M	-$0.27	N/A

Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market.

Entera Bio's return on equity of -83.31% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Entera Bio	N/A	-83.31%	-70.83%

In the previous week, Entera Bio had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for Entera Bio and 0 mentions for Applied Therapeutics. Entera Bio's average media sentiment score of 0.93 beat Applied Therapeutics' score of 0.00 indicating that Entera Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Entera Bio	Positive

Summary

Entera Bio beats Applied Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Applied Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLT vs. The Competition

Export

Metric	Applied Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.86M	$3.30B	$6.65B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-1.03	18.68	24.73	23.76
Price / Sales	15.86	297.55	507.94	105.22
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	0.21	8.06	10.36	6.72
Net Income	-$105.62M	$23.83M	$3.56B	$337.35M
7 Day Performance	N/A	-2.51%	-0.96%	-1.21%
1 Month Performance	N/A	2.22%	1.26%	1.41%
1 Year Performance	-73.32%	36.40%	20.46%	23.64%

Applied Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLT Applied Therapeutics	1.4702 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30
PMVP PMV Pharmaceuticals	2.6703 of 5 stars	$1.19 +2.6%	$5.00 +320.2%	-0.9%	$61.87M	N/A	N/A	50	Positive News Analyst Upgrade
EDSA Edesa Biotech	1.998 of 5 stars	$7.09 +3.4%	$5.00 -29.5%	+152.0%	$61M	N/A	N/A	20	Positive News
SCLX Scilex	0.4167 of 5 stars	$7.58 +5.7%	N/A	+13.9%	$60.88M	$30.25M	N/A	80	Gap Up
PDSB PDS Biotechnology	3.5184 of 5 stars	$1.22 +13.0%	$9.00 +637.7%	-39.8%	$60.28M	N/A	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLT) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Applied Therapeutics (APLT) Competitors

APLT vs. PMVP, EDSA, SCLX, PDSB, and ENTX

How does Applied Therapeutics compare to PMV Pharmaceuticals?

Summary

How does Applied Therapeutics compare to Edesa Biotech?

Summary

How does Applied Therapeutics compare to Scilex?

Summary

How does Applied Therapeutics compare to PDS Biotechnology?

Summary

How does Applied Therapeutics compare to Entera Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT vs. The Competition

Applied Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Applied Therapeutics (APLT) Competitors

APLT vs. PMVP, EDSA, SCLX, PDSB, and ENTX

How does Applied Therapeutics compare to PMV Pharmaceuticals?

Do analysts recommend APLT or PMVP?

Do institutionals and insiders hold more shares of APLT or PMVP?

Which has preferable valuation & earnings, APLT or PMVP?

Is APLT or PMVP more profitable?

Does the media favor APLT or PMVP?

Which has more volatility and risk, APLT or PMVP?

Summary

How does Applied Therapeutics compare to Edesa Biotech?

Does the media favor APLT or EDSA?

Which has more risk & volatility, APLT or EDSA?

Which has stronger valuation & earnings, APLT or EDSA?

Do insiders & institutionals hold more shares of APLT or EDSA?

Do analysts rate APLT or EDSA?

Is APLT or EDSA more profitable?

Summary

How does Applied Therapeutics compare to Scilex?

Which has more volatility and risk, SCLX or APLT?

Do analysts rate SCLX or APLT?

Is SCLX or APLT more profitable?

Do institutionals & insiders have more ownership in SCLX or APLT?

Does the media prefer SCLX or APLT?

Which has better valuation and earnings, SCLX or APLT?

Summary

How does Applied Therapeutics compare to PDS Biotechnology?

Which has more volatility & risk, PDSB or APLT?

Which has stronger valuation and earnings, PDSB or APLT?

Do analysts rate PDSB or APLT?

Do institutionals and insiders have more ownership in PDSB or APLT?

Is PDSB or APLT more profitable?

Does the media refer more to PDSB or APLT?

Summary

How does Applied Therapeutics compare to Entera Bio?

Do institutionals and insiders believe in APLT or ENTX?

Do analysts prefer APLT or ENTX?

Which has higher valuation and earnings, APLT or ENTX?

Which has more risk and volatility, APLT or ENTX?

Is APLT or ENTX more profitable?

Does the media favor APLT or ENTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT vs. The Competition

Applied Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools